Journal of the Neurological Sciences
Volume 229 , Pages 13-20 , 15 March 2005

Cerebral small vessel disease: how does it progress?

  • Klaus Schmidtke

      Affiliations

    • Center for Geriatric Medicine and Gerontology, University Clinic Freiburg, Lehener Str. 88, 79106 Freiburg, Germany
    • Corresponding Author InformationCorresponding authors. Klaus Schmidtke is to be contacted at Tel./fax: +49 761 2707077. Michael Hüll, Department of Psychiatry and Psychotherapy, University Clinic Freiburg, Hauptstr. 5, 79104 Freiburg, Germany. Tel.: +49 761 2706658.
    • ,
  • Michael Hüll

      Affiliations

    • Center for Geriatric Medicine and Gerontology, University Clinic Freiburg, Lehener Str. 88, 79106 Freiburg, Germany
    • Department of Psychiatry and Psychotherapy, University Clinic Freiburg, Hauptstr. 5, 79104 Freiburg, Germany
    • Corresponding Author InformationCorresponding authors. Klaus Schmidtke is to be contacted at Tel./fax: +49 761 2707077. Michael Hüll, Department of Psychiatry and Psychotherapy, University Clinic Freiburg, Hauptstr. 5, 79104 Freiburg, Germany. Tel.: +49 761 2706658.

References 

  1. Almkvist O, Backman L, Basun H, Wahlund LO. Patterns of neuropsychological performance in Alzheimer's disease and vascular dementia. Cortex. 1993;29:661–673
  2. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J. Neurol. Sci. 2002;203–204:147–151
  3. Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neill D, et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry. 2001;16:499–503
  4. Bennett HP, Corbett AJ, Gaden S, Grayson DA, Kril JJ, Broe GA. Subcortical vascular disease and functional decline: a 6-year predictor study. J. Am. Geriatr. Soc. 2002;50:1969–1977
  5. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Donepezil 307 Vascular Dementia Study Group Efficacy and tolerability of Donepezil in vascular dementia. Stroke. 2003;34:2322–2332
  6. Bowler J. Epidemiology: identifying vascular cognitive impairment. Int. Psychogeriatr. 2003;15(Suppl. 1):115–122
  7. Bracco L, Campani D, Baratti E, Lippi A, Inzitari D, Pracucci G, et al. Relation between MRI features and dementia in cerebrovascular disease patients with leukoaraiosis: a longitudinal study. J. Neurol. Sci. 1993;120:131–136
  8. Cannatà AP, Alberoni M, Franceschi M, Mariani C. Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease. Dementia. 2001;13:101–111
  9. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177–1181
  10. Corbett A, Bennett H, Kos S. Cognitive dysfunction following subcortical infarction. Arch. Neurol. 1994;10:999–1007
  11. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999;30:529–536
  12. De Groot JC, De Leeuw FE, Oudkerk M, Van Gijn J, Hofman A, Jolles J, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann. Neurol. 2002;52:335–341
  13. De Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125:765–772
  14. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J. Neural Transm. 2000;59:23–30[Suppl.]
  15. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of Galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283–1290
  16. Fazekas F, Ropele S, Schmidt R. Can small-vessel disease-related cerebral anormalities be used as a surrogate marker for vascular dementia trials?. J. Neuronal Transm. 2002;62:61–67[Suppl.]
  17. Ferris SH. General measures of cognition. Int. Psychogeriatr. 2003;15(Suppl. 1):215–217
  18. Fischer P, Gatterer G, Marterer A, Simanyi M, Danielczyk W. Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct demetia. Acta Psychiatr. Scand. 1990;81:551–553
  19. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Multiple Sclerosis Collaborative Research Group Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Ann. Neurol. 2000;48:885–892
  20. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet. 1998;352:1347–1351
  21. Frisoni GB, Galluzzi S, Bresciani L, Zanetti O, Geroldi C. Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. J. Neurol. 2002;249:1423–1432
  22. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet. 2000;356:628–634
  23. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974 (Jul 27);2(7874):207–210
  24. Inzitari D, Erkinjuntti T, Wallin A, Del Ser T, Romanelli M, Pantoni L. Subcortical vascular dementia as a specific target for clinical trials. Ann. N.Y. Acad. Sci. 2000;903:510–521
  25. Kittner B, De Deyn PP, Erkinjuntti T. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann. N.Y. Acad. Sci. 2000;903:535–541
  26. Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Michel JP, et al. Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke. 2004;35:410–414
  27. Kurz A, Brashear HR. Galantamine is save and effective for 36 months in patients with probable vascular dementia or Alzheimer's disease and cerebrovascular disease. Poster presented at the 3rd International Congress on Vascular Dementia, Prague, October 23–26, 2003.
  28. Launer LJ. Epidemiology of white-matter lesions. Int. Psychogeriatr. 2003;15(Suppl. 1):99–103
  29. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125:765–772
  30. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease?. Stroke. 2002;33:1981–1985
  31. Miyao S, Takano A, Teramoto J, Takahashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke. 1992;23:1434–1438
  32. Möbius HJ, Stöffler A. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc. Dis. 2002;13(Suppl. 2):61–66
  33. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J. Neurol. Sci. 2002;203–204:141–146
  34. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-months study in 208 patients. Am. J. Alzheimer's Dis. other Dement. 2003;18:265–272
  35. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2:89–98
  36. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 2000;175:124–134
  37. Pantoni L, Simoni M. Pathophysiology of cerebral small vessels in vascular cognitive impairment. Int. Psychogeriatr. 2003;15(Suppl. 1):59–65
  38. Passmore AP, Pratt AD, Perdomo CA. A comparison of the cognitive benefits of Donepezil in patients with cortical and subcortical vascular dementia: a subanalysis of two 24-week, randomized, double-blind, placebo-controlled trials. In: Oral presentation at the 3rd International Congress on Vascular Dementia, Prague, October 23–26. 2003;
  39. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Neurology. 2000;54:447–451
  40. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  41. Sabri O, Ringelstein EB, Hellwig D, Schneider R, Schreckenberger M, Kaiser HJ, et al. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke. 1999;30:556–566
  42. Sabri O, Hellwig D, Schreckenberger M, Schneider R, Kaiser HJ, Wagenknecht G, et al. One-year follow-up of neuropsychology, MRI, rCBF and glucose metabolism (rMRGlu) in cerebral microangiopathy. Nuklearmedizin. 2000;39:43–49
  43. Schmidt R, Schmidt H, Fazekas F. Vascular risk factors in dementia. J. Neurol. 2000;247:81–87
  44. Schmidt R, Schmidt H, Kapeller P, Enzinger C, Ropele S, Saurugg R, et al. The natural course of MRI white matter hyperintensities. J. Neurol. Sci. 2002;203–204:253–257
  45. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F, Austrian Stroke Prevention Study . Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet. 2003;361:2046–2048
  46. Schmidt R, Schmidt H, Lapeller P, Fazekas F. Slow progression of white-matter changes. Int. Psychogeriatr. 2003;15(Suppl. 1):173–176
  47. Schmidtke K, Hüll M. Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia. J. Neurol. Sci. 2002;9:419–429
  48. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch. Neurol. 2001;58:1654–1659
  49. Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on number of chronic disabilities. Am. J. Med. 1986;80:429–434
  50. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. PROGRESS Collaborative Group Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003;163:1069–1075
  51. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia. An interobserver study. Stroke. 2003;34:1907–1912
  52. Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology. 1998;51:319–320
  53. Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 2001;57:714–716
  54. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke. 1996;27:30–36
  55. Whitman GT, Tang Y, Lin A, Baloh RW. A prospective study of cerebral white matter abnormalities in oder people with gait dysfunction. Neurology. 2001;57:990–994
  56. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479–486
  57. Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst. Rev. 2000;4:CD001296
  58. Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int. J. Geriatr. Psychiatry. 2000;15:803–812

PII: S0022-510X(04)00473-3

doi: 10.1016/j.jns.2004.11.048

Journal of the Neurological Sciences
Volume 229 , Pages 13-20 , 15 March 2005

Article Tools